Literature DB >> 8085473

Conduct disorder patients 20 years later: a personal follow-up study.

A Storm-Mathisen1, P Vaglum.   

Abstract

As a part of a larger study, 75 consecutive patients with conduct disorder (48% men, median age 15, range: 6-19 years) were followed up after 18-21 years (mean: 19) with a clinical interview using DSM-III criteria. At follow-up, 47% had no Axis I disorder, 24% an anxiety disorder, 25% a substance abuse disorder and only one a psychotic disorder. Thirty-three percent fulfilled the criteria of an antisocial personality disorder. An additional anxiety disorder at the time of the primary examination was a strong predictor of a poor outcome, as was also criminal offences. The study shows the severe prognosis of conduct disorder and the importance of this disorder as an antecedent to substance abuse. However, since nearly half of these patients developed into a healthy state during the 20-year follow-up period, work should be continued to develop better treatment for these patients.

Entities:  

Mesh:

Year:  1994        PMID: 8085473     DOI: 10.1111/j.1600-0447.1994.tb01539.x

Source DB:  PubMed          Journal:  Acta Psychiatr Scand        ISSN: 0001-690X            Impact factor:   6.392


  3 in total

1.  Adolescent outcomes of childhood conduct disorder among clinic-referred boys: predictors of improvement.

Authors:  Benjamin B Lahey; Rolf Loeber; Jeffrey Burke; Paul J Rathouz
Journal:  J Abnorm Child Psychol       Date:  2002-08

2.  Testing developmental pathways to antisocial personality problems.

Authors:  Sofia Diamantopoulou; Frank C Verhulst; Jan van der Ende
Journal:  J Abnorm Child Psychol       Date:  2010-01

3.  The impact of ADHD symptoms and global impairment in childhood on working disability in mid-adulthood: a 28-year follow-up study using official disability pension records in a high-risk in-patient population.

Authors:  Marianne Mordre; Berit Groholt; Berit Sandstad; Anne Margrethe Myhre
Journal:  BMC Psychiatry       Date:  2012-10-19       Impact factor: 3.630

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.